SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2016.
Summary of Results of Operations
Revenues for the fiscal year ended 2016 increased 77% to $1,289,000 compared with prior year-end revenues of $729,000.
